Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

7.910 +0.170 (+2.20%)
Streaming Delayed Price Updated: 11:03 AM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 411,612
Open 7.560
Bid (Size) 7.910 (2)
Ask (Size) 7.930 (2)
Prev. Close 7.740
Today's Range 7.550 - 7.920
52wk Range 4.250 - 16.73
Shares Outstanding 98,983,261
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year
Wave Life plans a 2026 NDA filing for WVE-N531 after positive Phase 2 data in Duchenne muscular dystrophy, showing functional gains and biomarker improvements. 
Via Benzinga
Exposures Product Safety
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531
From Wave Life Sciences USA, Inc.
Via GlobeNewswire

Performance

YTD
-40.6%
-40.6%
1 Month
-21.3%
-21.3%
3 Month
-36.1%
-36.1%
6 Month
-4.7%
-4.7%
1 Year
+25.4%
+25.4%

More News

Read More
Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
What's Next: WAVE Life Sciences's Earnings Preview
Via Benzinga
Earnings Scheduled For March 4, 2025
Via Benzinga
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences to Present at Jefferies London Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
1 Brand-New Big Reason to Buy This Biotech Stock Right Now
Via The Motley Fool
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Via Investor's Business Daily
Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?
Via Benzinga
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Via MarketBeat
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
Via Benzinga
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
Via Investor's Business Daily

Frequently Asked Questions

Is Wave Life Sciences Ltd. - Ordinary Shares publicly traded?
Yes, Wave Life Sciences Ltd. - Ordinary Shares is publicly traded.
What exchange does Wave Life Sciences Ltd. - Ordinary Shares trade on?
Wave Life Sciences Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares?
The ticker symbol for Wave Life Sciences Ltd. - Ordinary Shares is WVE on the Nasdaq Stock Market
What is the current price of Wave Life Sciences Ltd. - Ordinary Shares?
The current price of Wave Life Sciences Ltd. - Ordinary Shares is 7.910
When was Wave Life Sciences Ltd. - Ordinary Shares last traded?
The last trade of Wave Life Sciences Ltd. - Ordinary Shares was at 04/02/25 11:03 AM ET
What is the market capitalization of Wave Life Sciences Ltd. - Ordinary Shares?
The market capitalization of Wave Life Sciences Ltd. - Ordinary Shares is 782.96M
How many shares of Wave Life Sciences Ltd. - Ordinary Shares are outstanding?
Wave Life Sciences Ltd. - Ordinary Shares has 783M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS